Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 939.00
0.00 (0.00%)
Aug 19, 2026, 2:59 PM CST
Lin BioScience Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Selling, General & Admin | 1,918 | 1,244 | 356.55 | 242.75 | 124.26 | 93.52 |
Research & Development | 2,052 | 1,613 | 1,101 | 854.07 | 320.87 | 244.76 |
Operating Expenses | 3,970 | 2,857 | 1,458 | 1,097 | 445.13 | 338.28 |
Operating Income | -3,970 | -2,857 | -1,458 | -1,097 | -445.13 | -338.28 |
Interest Expense | -2.02 | -0.97 | -1 | -1.2 | -0.88 | -0.07 |
Interest & Investment Income | 524.15 | 215.87 | 122.52 | 4.49 | 1.19 | 0.19 |
Currency Exchange Gain (Loss) | 5.3 | 5.3 | 4.89 | -1.95 | 8.87 | -0.53 |
Other Non Operating Income (Expenses) | 15.77 | -0.05 | 0.3 | 4.95 | -41.93 | -151.95 |
EBT Excluding Unusual Items | -3,427 | -2,637 | -1,331 | -1,091 | -477.87 | -490.63 |
Gain (Loss) on Sale of Investments | - | - | 1.57 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.22 |
Other Unusual Items | -0.01 | -0.01 | 1.07 | - | - | - |
Pretax Income | -3,427 | -2,637 | -1,328 | -1,091 | -477.87 | -490.41 |
Income Tax Expense | -53.6 | -55.33 | -69.6 | -29.72 | -18.44 | -9.51 |
Earnings From Continuing Operations | -3,374 | -2,582 | -1,259 | -1,061 | -459.43 | -480.9 |
Minority Interest in Earnings | 1,764 | 1,219 | 514.45 | 373.63 | 145.91 | 46.21 |
Net Income | -1,609 | -1,363 | -744.27 | -687.19 | -313.52 | -434.7 |
Net Income to Common | -1,609 | -1,363 | -744.27 | -687.19 | -313.52 | -434.7 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 83 | 82 | 79 | 74 | 72 | 69 |
Shares Outstanding (Diluted) | 83 | 82 | 79 | 74 | 72 | 69 |
Shares Change | 3.48% | 4.46% | 6.24% | 3.14% | 4.27% | 10.73% |
EPS (Basic) | -19.43 | -16.60 | -9.47 | -9.29 | -4.37 | -6.32 |
EPS (Diluted) | -19.43 | -16.60 | -9.47 | -9.29 | -4.37 | -6.32 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2,284 | -1,449 | -1,025 | -1,015 | -383.4 | -291.96 |
Free Cash Flow Per Share | -27.58 | -17.64 | -13.04 | -13.72 | -5.34 | -4.24 |
EBITDA | -3,956 | -2,849 | -1,451 | -1,091 | -442.62 | -336.79 |
D&A For EBITDA | 14.63 | 7.66 | 6.56 | 5.85 | 2.51 | 1.48 |
EBIT | -3,970 | -2,857 | -1,458 | -1,097 | -445.13 | -338.28 |